Topline data from Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT study reinforces ...

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.Fourth positive DSMB ...

Tyr Pharma (ATYR) announced a publication demonstrating the mechanism of action for its lead therapeutic candidate, efzofitimod, in the journal ...

圣地亚哥 - 市值约2.99亿美元的临床阶段生物科技公司aTyr Pharma, Inc. (NASDAQ: ATYR )宣布，一项同行评议发表的研究结果支持其主要候选药物efzofitimod在治疗间质性肺疾病（ILD）方面的治疗潜力。根据InvestingPro数据，该公司保持着5.4倍的流动比率，显示出强劲的流动性状况，尽管分析师预计公司在本年度可能面临销售挑战。这项发表在《Science ...

Peer-reviewed publication validates efzofitimod’s unique anti-inflammatory mechanism of action on macrophages through ...

This new article published in Genes & Diseases highlights the critical role of tRNA-derived small RNAs (tsRNAs) in digestive ...

This new article published in Genes & Diseases highlights the critical role of tRNA-derived small RNAs (tsRNAs) in digestive ...

This new article published in Genes & Diseases highlights the critical role of tRNA-derived small RNAs (tsRNAs) in digestive ...

This film creatively illustrates the process of protein synthesis through dance, symbolizing the assembly of amino acids into proteins. It explains how genes encode instructions for amino acid ...

SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-cl ...

Mitochondrial deoxyribonucleic acid (mtDNA) is essential for cellular energy production and overall cell function.

The pioneering research of UC Santa Cruz's Upasna Sharma to determine how a father's life experiences and environment can ...